Difference between revisions of "Part:BBa K3771006"
Marvinang02 (Talk | contribs) |
|||
(5 intermediate revisions by 2 users not shown) | |||
Line 4: | Line 4: | ||
<br><b style="font-size:1.3rem">Description</b> | <br><b style="font-size:1.3rem">Description</b> | ||
− | <p>JJU (cysteine lyase) is an enzyme weighing approximately | + | <p>JJU (cysteine lyase) is an enzyme weighing approximately 45.1 kDa. JJU catalyzes the beta replacement reaction of L-cysteine and sulfite to form L-cysteate and hydrogen sulfide[1].</p> |
<br><b style="font-size:1.3rem">Usage</b> | <br><b style="font-size:1.3rem">Usage</b> | ||
− | <br> | + | <br>JJU enzyme was used <i>in vitro</i> testing of taurine production. The sequence for JJU enzyme and trc promoter were ligated and transformed into <i>E. coli</i> to calculate taurine production using high-performance liquid chromatography (HPLC). A 6xHis-tag is added to the C-terminal of the JJU protein, allowing for confirmation of JJU expression by western blot using the anti-6xHis antibody.<br> |
− | + | ||
<html> | <html> | ||
<div style="width=100%; display:flex; align-items: center; justify-content: center;"> | <div style="width=100%; display:flex; align-items: center; justify-content: center;"> | ||
Line 15: | Line 14: | ||
</div> | </div> | ||
</html> | </html> | ||
− | <p align="center"> | + | <p align="center">Fig. 1. Taurine pathways in <i>E. coli</i> [1,2].</p> |
<p>JJU is an enzyme that is part of the JJU-CoaBC taurine production pathway, one of three possible taurine synthesis pathways. Its main function is to convert L-cysteine to L-cystate, which then becomes taurine by CoaBC[1]. </p> | <p>JJU is an enzyme that is part of the JJU-CoaBC taurine production pathway, one of three possible taurine synthesis pathways. Its main function is to convert L-cysteine to L-cystate, which then becomes taurine by CoaBC[1]. </p> | ||
Line 25: | Line 24: | ||
<html> | <html> | ||
− | + | The <i>jju</i> sequence synthesized by IDT was amplified by PCR and ligated to <i>trc</i> promoter (<a href="https://parts.igem.org/Part:BBa_K864400" alt="" target="_blank">BBa_K864400</a>) in the pET28a cloning vector.<br> | |
</html> | </html> | ||
<html> | <html> | ||
Line 33: | Line 32: | ||
</div> | </div> | ||
</html> | </html> | ||
− | <p align="center"> | + | <p align="center">Fig. 2. Agarose gel electrophoresis results showing amplified <i>jju</i> gene fragment</p> |
Line 46: | Line 45: | ||
</div> | </div> | ||
</html> | </html> | ||
− | <p align="center"> | + | <p align="center">Fig. 3. Confirmation of JJU expression by SDS-PAGE. M: Marker; Lane 1: whole cell of JJU in BL21(DE3); Lane 2: soluble protein of JJU in BL21(DE3) (~43 kDa); |
+ | Lane 3: whole cell of CoaBC in BL21(DE3); Lane 4: soluble protein of CoaBC in BL21(DE3) (~45.1 kDa)</p> | ||
− | <br>Whole cell and supernatant JJU and CoaBC samples were collected and added in a JJU:CoaBC volume ratio of 1:1, 2:1, and 1:2. High-performance liquid chromatography (HPLC) was conducted to determine taurine concentration. Because JJU concentrations were lower, two times as much JJU supernatant volume compared to CoaBC supernatant volume was required to produce a significant amount of taurine. As shown in | + | <br>Whole cell and supernatant JJU and CoaBC samples were collected and added in a JJU:CoaBC volume ratio of 1:1, 2:1, and 1:2. High-performance liquid chromatography (HPLC) was conducted to determine taurine concentration. Because JJU concentrations were lower, two times as much JJU supernatant volume compared to CoaBC supernatant volume was required to produce a significant amount of taurine. As shown in Fig. 2, 2:1 ratio of JJU to CoaBC supernatant volume had the highest taurine concentration of around 95 mg/L. <br> |
<html> | <html> | ||
<div style="width=100%; display:flex; align-items: center; justify-content: center;"> | <div style="width=100%; display:flex; align-items: center; justify-content: center;"> | ||
− | <img src="https://2021.igem.org/wiki/images/ | + | <img src="https://2021.igem.org/wiki/images/2/27/T--NCKU_Tainan--invitro1.png" style="width:50%;"> |
</div> | </div> | ||
</html> | </html> | ||
− | <p align="center"> | + | <p align="center">Fig. 4. Taurine production of both JJU and CoaBC in BL21(DE3) in whole cell and soluble protein samples</p> |
− | + | <b style="font-size:1.1rem">Taurine Production of JJU in <i>E. coli</i> BD7G strain</b> | |
− | + | ||
<br>Since JJU expression in BL21(DE3) strain was not prominent in the supernatant, we performed another <i>in vitro</i> test in which <i>P<sub>T7</sub>-jju</i> was transformed into BD7G strain instead of the BL21(DE3) strain. The BD7G strain contains chaperone protein GroELS that aids in protein folding [1]. SDS-PAGE results confirm JJU expression in both supernatant and whole cell samples.<br> | <br>Since JJU expression in BL21(DE3) strain was not prominent in the supernatant, we performed another <i>in vitro</i> test in which <i>P<sub>T7</sub>-jju</i> was transformed into BD7G strain instead of the BL21(DE3) strain. The BD7G strain contains chaperone protein GroELS that aids in protein folding [1]. SDS-PAGE results confirm JJU expression in both supernatant and whole cell samples.<br> | ||
Line 67: | Line 66: | ||
</div> | </div> | ||
</html> | </html> | ||
− | <p align="center"> | + | <p align="center">Fig. 5. Confirmation of JJU expression by SDS-PAGE. M: Marker; Lane 1: whole cell of JJU in BD7G; Lane 2: soluble protein of JJU in BD7G (~43 kDa); |
+ | Lane 3: whole cell of CoaBC in BL21(DE3); Lane 4: soluble protein of CoaBC in BL21(DE3) (~45.1 kDa)</p> | ||
− | <br>The whole cell and supernatant JJU and CoaBC samples are collected and added in a JJU:CoaBC volume ratio of 1:1, 2:1, and 1:2. When <i>P<sub>T7</sub>-jju</i> was transformed into the BD7G strain, 1:1 ratio of JJU to CoaBC supernatant had the highest taurine production, as shown in | + | <br>The whole cell and supernatant JJU and CoaBC samples are collected and added in a JJU:CoaBC volume ratio of 1:1, 2:1, and 1:2. When <i>P<sub>T7</sub>-jju</i> was transformed into the BD7G strain, 1:1 ratio of JJU to CoaBC supernatant had the highest taurine production, as shown in Fig. 6. This suggests the activity level of JJU does not significantly differ from that of CoaBC, and both are equally crucial and effective in converting L-cysteine to taurine.<br> |
<html> | <html> | ||
<div style="width=100%; display:flex; align-items: center; justify-content: center;"> | <div style="width=100%; display:flex; align-items: center; justify-content: center;"> | ||
− | <img src="https://2021.igem.org/wiki/images/ | + | <img src="https://2021.igem.org/wiki/images/9/9d/T--NCKU_Tainan--invitro2.png" style="width:50%;"> |
</div> | </div> | ||
</html> | </html> | ||
− | <p align="center"> | + | <p align="center">Fig. 6. Taurine production of JJU in BD7G and CoaBC in BL21(DE3) in soluble protein samples</p> |
Latest revision as of 03:44, 22 October 2021
JJU-6xHis
Description
JJU (cysteine lyase) is an enzyme weighing approximately 45.1 kDa. JJU catalyzes the beta replacement reaction of L-cysteine and sulfite to form L-cysteate and hydrogen sulfide[1].
Usage
JJU enzyme was used in vitro testing of taurine production. The sequence for JJU enzyme and trc promoter were ligated and transformed into E. coli to calculate taurine production using high-performance liquid chromatography (HPLC). A 6xHis-tag is added to the C-terminal of the JJU protein, allowing for confirmation of JJU expression by western blot using the anti-6xHis antibody.
Fig. 1. Taurine pathways in E. coli [1,2].
JJU is an enzyme that is part of the JJU-CoaBC taurine production pathway, one of three possible taurine synthesis pathways. Its main function is to convert L-cysteine to L-cystate, which then becomes taurine by CoaBC[1].
Characterization
The jju sequence synthesized by IDT was amplified by PCR and ligated to trc promoter (BBa_K864400) in the pET28a cloning vector.
Fig. 2. Agarose gel electrophoresis results showing amplified jju gene fragment
Taurine Production of JJU in E. coli BL21(DE3) strain
In our in vitro testing of taurine production by JJU, JJU was transformed into E. coli BL21(DE3) strain. Supernatant (S) and whole cell (WC) samples were collected to confirm extracellular and intracellular protein expression by SDS-PAGE.
Fig. 3. Confirmation of JJU expression by SDS-PAGE. M: Marker; Lane 1: whole cell of JJU in BL21(DE3); Lane 2: soluble protein of JJU in BL21(DE3) (~43 kDa); Lane 3: whole cell of CoaBC in BL21(DE3); Lane 4: soluble protein of CoaBC in BL21(DE3) (~45.1 kDa)
Whole cell and supernatant JJU and CoaBC samples were collected and added in a JJU:CoaBC volume ratio of 1:1, 2:1, and 1:2. High-performance liquid chromatography (HPLC) was conducted to determine taurine concentration. Because JJU concentrations were lower, two times as much JJU supernatant volume compared to CoaBC supernatant volume was required to produce a significant amount of taurine. As shown in Fig. 2, 2:1 ratio of JJU to CoaBC supernatant volume had the highest taurine concentration of around 95 mg/L.
Fig. 4. Taurine production of both JJU and CoaBC in BL21(DE3) in whole cell and soluble protein samples
Taurine Production of JJU in E. coli BD7G strain
Since JJU expression in BL21(DE3) strain was not prominent in the supernatant, we performed another in vitro test in which PT7-jju was transformed into BD7G strain instead of the BL21(DE3) strain. The BD7G strain contains chaperone protein GroELS that aids in protein folding [1]. SDS-PAGE results confirm JJU expression in both supernatant and whole cell samples.
Fig. 5. Confirmation of JJU expression by SDS-PAGE. M: Marker; Lane 1: whole cell of JJU in BD7G; Lane 2: soluble protein of JJU in BD7G (~43 kDa); Lane 3: whole cell of CoaBC in BL21(DE3); Lane 4: soluble protein of CoaBC in BL21(DE3) (~45.1 kDa)
The whole cell and supernatant JJU and CoaBC samples are collected and added in a JJU:CoaBC volume ratio of 1:1, 2:1, and 1:2. When PT7-jju was transformed into the BD7G strain, 1:1 ratio of JJU to CoaBC supernatant had the highest taurine production, as shown in Fig. 6. This suggests the activity level of JJU does not significantly differ from that of CoaBC, and both are equally crucial and effective in converting L-cysteine to taurine.
Fig. 6. Taurine production of JJU in BD7G and CoaBC in BL21(DE3) in soluble protein samples
References
BRENDA - Information on EC 4.4.1.10 - cysteine lyase. Brenda-enzymes.org. Published 2021. Accessed October 6, 2021. https://www.brenda-enzymes.org/enzyme.php?ecno=4.4.1.10
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]